GlobeNewswire

SparkLabs Engages with Argon Group to Launch the First Startup Accelerator Security Token Offering

Dela

The Largest Accelerator Network in Asia Partners with Argon Group, a leading digital finance advisory firm, and Swarm.Fund, the first security token platform, to Democratize Venture Capital Access

 

PALO ALTO, Calif., May 11, 2018 (GLOBE NEWSWIRE) -- SparkLabs Group, which has the largest accelerator network in Asia and operates global venture capital funds, has engaged with Argon Group, a leading digital finance advisory firm, to launch the first startup accelerator security token offering through their Smart City & Smart Planet Fund (sparklabs.tokenhub.com).

The SparkLabs token is not a utility token and is simply a smart contract that represents an investor's ("Limited Partners") equity into its fund vehicle that will have equal holdings in start-up companies that are associated with SparkLabs IoT & Smart City Accelerator in Songdo, South Korea and SparkLabs Cultiv8 Accelerator in Orange, Australia.

"SparkLabs has been very conservative in our approach and viewpoints on the cryptocurrency space and token offerings.  We have been concerned that many utility tokens are in fact securities and have viewed this space with some trepidation.  After meticulous diligence, we have now decided to jump into the pool a bit with a security token offering that we believe is conservative and provides a better understanding for venture capitalists on how this can affect our industry in the years to come," stated Jimmy Kim, Co-founder of SparkLabs Group and former CFO of Nexon (South Korea's largest onling gaming company).  Additionally, Mr. Kim's most recent startup, N3N, was Cisco's first IoT investment.

Graduates of SparkLabs accelerators have an average raise size of over $3.5 million with 80% of the startups receiving funding after the program.  SparkLabs' startups also average over $500,000 in funds raised prior to entering the accelerator programs.

"We believe our Smart City & Smart Planet Fund allows people across the globe to invest into two accelerator funds that can truly change the world in terms of urban innovation, innovation in agriculture, and how we interact with our planet. Both accelerators have excellent partners, such as Australia's Government of New South Wales which generously provided access to over 30,000 acres of farmland for our startups to utilize as a test bed," explained Frank Meehan, Co-founder of SparkLabs Group.  Mr. Meehan was born and raised in Australia and is currently living in London. Prior to launching SparkLabs, he was best known for leading DeepMind's Series A (acquired by Google) and sat on Siri's board of directors until it was acquired by Apple.

"Argon Group is excited to be working with SparkLabs on this new and creative development for venture capital.  I believe that SparkLabs is an imaginative accelerator, and, in my view, it comes as no surprise to me that they are leading an effort combining both pioneering urban and environment planning and an innovative approach to capital raising,"  said Elliot Han, Managing Director at Argon Group.

About SparkLabs Group
SparkLabs Group (www.sparklabsgroup.com) is comprised of SparkLabs accelerator network, one of Asia's premier startup accelerators; SparkLabs Global Ventures, a leading global seed stage fund; SparkLabs Ventures, a localized early-stage fund (Series A & B) in South Korea; SparkLabs Capital, a late stage investment vehicle.  SparkLabs accelerator network consists of SparkLabs Korea (Seoul), SparkLabs China (Beijing and launching Shanghai, Chengdu and Shenzen), SparkLabs IoT & Smart Cities (Songdo, South Korea), SparkLabs Taipei, SparkLabs Cultiv8 (Sydney) and Ping An FinTech Accelerator, Powered by SparkLabs (Shenzhen & Hong Kong).

About Argon Group
Argon Group is a leading boutique investment bank focused exclusively on the digital finance and token-based capital markets. Argon Group has developed an end-to-end offering, supporting the full process of raising capital in digital capital markets as well as aftermarket trading and support.  Key clients include Blockchain Capital, Civic, Storj, Science Blockchain, Protos, TheKey and others.

About Swarm Fund
Swarm Fund is a blockchain-based resource for private equity. It's a fully decentralized capital market place that democratizes investing by using the power of the blockchain to open up alternative investment classes to investors through funds using cryptocurrency tokens. It makes traditionally exclusive investment opportunities, such as private equity and hedge funds, inclusive for the Swarm by pooling together smaller investments into larger, institutional-sized blocks, providing fund managers access to arguably untapped capital stack. 

The Swarm blockchain allows real world investment opportunities to be "tokenized" using the SRC20 protocol, a cryptographic standard for security tokens.

Contact:            
Bernard Moon, Co-founder, SparkLabs Group
+1-650-454-5244 or bernard@sparklabsglobal.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: SparkLabs via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Investerarmöten våren 201915.2.2019 08:46:00Pressmeddelande

15 februari 2019 PRESSRELEASE Arcoma har som ambition att fortsätta öka sitt aktieägarfokus och kontinuerligt förbättra kommunikationen med aktieägare. Under våren 2019 kommer Arcoma medverka på flertalet investerarmöten där aktuella händelser och aktiviteter presenteras. Här ges en ökad inblick i bolagets vision och strategier samt en möjlighet till att ställa frågor till bolagets ledning. SvD Börsplus Temadag "Dubblare" Dag, tid och plats: 5 mars, kl. 13.00, GT 30, Grev Turegatan 30, Stockholm Stockholm Corporate Finance Life Science event Dag, tid och plats: 14 mars, kl. 07.30, Berns, Kammarsalen, Stockholm Redeyes Medtech & Diagnostics event Dag, tid och plats: 14:e maj, Redeye, Mäster Samuelsgatan 42, Stockholm För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soderqvist at arcoma.se Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalite

Corline Biomedical AB: Första patient doserad med Renaparin®15.2.2019 08:42:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man inkluderat första patienten i fas 1-studien RENAPAIR 01. Patienten inkluderades vid transplantationsavdelningen på Uppsala Akademiska sjukhus. Renaparin® är en produkt under utveckling för att förbättra njurtransplantation. I Corlines studie RENAPAIR 01 utvärderas produkten med avseende på tolerabilitet och säkerhet. Studien öppnades för patientrekrytering i slutet av 2018 och första patient är nu doserad och inkluderad i studien. Totalt skall 18 patienter rekryteras och när de 4 första patienterna är utvärderade i Uppsala, öppnas också Karolinska Universitetssjukhuset i Huddinge för rekrytering till studien. Henrik Nittmar, VD i Corline Biomedical AB, kommenterar "Det händer mycket i Corline för tillfället och alla arbetar hårt för att målbilden i bolaget skall uppfyllas. Det gäller såväl vår interna organisation som våra externa samarbetspartners. Därför är det extra roligt när vi når avgörande milstolpar i utvec

Corline Biomedical AB: Rekryterar Lars Olsson som Head of CMC14.2.2019 12:44:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man rekryterat Lars Olsson till den nyinrättade tjänsten som Head of CMC (Chemistry, Manufacturing & Control). Lars Olsson hade tidigare samma tjänst hos Wilson Therapeutics AB, som under 2018 förvärvades av amerikanska Alexion. Lars Olsson kommer att ansvara för Corlines samtliga aktiviteter inom tillverkning och kontroll relaterat till bolagets läkemedelsprodukter, med särskilt fokus på Renaparin® inför kommande fas 2- och fas 3-utveckling. I slutet av 2018 meddelade Corline att patientrekryteringen startar i bolagets fas 1-studie RENAPAIR 01, där produkten Renaparin®, som är under utveckling för att förbättra utfallet av njurtransplantation, utvärderas med avseende på tolerabilitet och säkerhet. Därmed tog en ny utvecklingsfas vid i bolaget i vilken alltmer resurser fokuseras på att förbereda den fortsatta kliniska utvecklingen av produkten genom fas 2 och fas 3 i syfte att slutligen kunna registrera produkten för k

Arcoma AB: Canon och Arcoma tecknar distributörsavtal för Turkiet14.2.2019 10:38:00Pressmeddelande

14 februari 2019 Canon Medical Systems i Turkiet och Arcoma har tecknat ett distributörsavtal som gör att Canon kommer att kunna sälja Arcomas produkter i Turkiet från och med den 15 februari 2019. Canon är sedan tidigare återförsäljare för Arcomas produkter i Nordamerika och utvalda länder i Europa. Detta samarbete utökas nu till Turkiet som är det första land i Canons Asien organisation att välja Arcoma som en formell partner. "Att vi stärker och formaliserar samarbetet med Canon även i Turkiet är ännu ett erkännande av Arcoma som leverantör av högkvalitativa röntgensystem. Canon i Turkiet förbereder ett flertal större upphandlingar till sjukhus där Arcomas lösningar ingår. Avtal som detta ingår i Arcomas strategi att utöka med nya försäljningskanaler och att expandera till nya länder för att skapa framtida tillväxt." kommenterar Arcomas VD, Jesper Söderqvist. För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soder

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum